MetaVia
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell MetaVia and other ETFs, options, and stocks.About MTVA
MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases.
CEOHyung-Heon Kim
CEOHyung-Heon Kim
Employees9
Employees9
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded2014
Founded2014
Employees9
Employees9
MTVA Key Statistics
Market cap18.22M
Market cap18.22M
Price-Earnings ratio-0.56
Price-Earnings ratio-0.56
Dividend yield—
Dividend yield—
Average volume477.37K
Average volume477.37K
High today$9.00
High today$9.00
Low today$7.86
Low today$7.86
Open price$8.24
Open price$8.24
Volume53.50K
Volume53.50K
52 Week high$30.25
52 Week high$30.25
52 Week low$6.05
52 Week low$6.05
Stock Snapshot
With a market cap of 18.22M, MetaVia(MTVA) trades at $8.14. The stock has a price-to-earnings ratio of -0.56.
On 2025-12-16, MetaVia(MTVA) stock traded between a low of $7.86 and a high of $9.00. Shares are currently priced at $8.14, which is +3.6% above the low and -9.6% below the high.
The MetaVia(MTVA)'s current trading volume is 53.5K, compared to an average daily volume of 477.37K.
During the past year, MetaVia(MTVA) stock moved between $6.05 at its lowest and $30.25 at its peak.
During the past year, MetaVia(MTVA) stock moved between $6.05 at its lowest and $30.25 at its peak.
People also own
Based on the portfolios of people who own MTVA. This list is generated using Robinhood data, and it’s not a recommendation.